demonstrate adequate reproducibility across multiple intended use sites. Additionally, precision and reproducibility of the device must be evaluated with specimens near the clinical decision threshold(s) and near the limits of reportable range. Precision studies must include evaluation of the controls. Precision of the device must be evaluated per specimen, in aggregate, and for repeat testing/invalid rate, as appropriate.

(v) Device performance data demonstrating appropriate device robustness, as determined to be appropriate by FDA. The study must assess the tolerance ranges for critical test and specimen parameters, as applicable.

(vi) Device performance data demonstrating linearity of quantitative results using samples covering the device measuring range, as applicable.

(vii) Device performance data demonstrating appropriate specimen stability for the intended specimen type(s) (*e.g.,* unstained cut-tissue section stability).

(viii) Clinical data generated using well-characterized clinical specimens representative of the intended use population demonstrating appropriate clinical performance of the device for its intended use, as determined to be appropriate by FDA.

(2) Labeling must include:

(i) An appropriate summary, as determined by FDA, of the performance studies performed and the results of those studies, including those that relate to all design verification and validation special controls.

(ii) A limiting statement, as appropriate, that explains that the test results are intended to be interpreted by a qualified or appropriately trained reader in conjunction with other diagnostic laboratory test results and/or pathology test results, relevant clinical information, and proper controls.

(iii) For those test systems intended to provide information that is essential for the safe and effective use of a corresponding approved oncology therapeutic product, language indicating that the test system is indicated for use with a corresponding FDA-approved oncology therapeutic product. Device labeling must be consistent with the information set forth in the corresponding FDA-approved oncology therapeutic product labeling.

(iv) For those test systems intended to provide information about known benefits and/or risks related to the use of a corresponding FDA-approved oncology therapeutic product but are not essential for the safe and effective use of the corresponding approved oncology therapeutic product, language summarizing the benefits and/or risks related to the use of a corresponding FDA-approved oncology therapeutic product that must be consistent with the information set forth in the corresponding FDA-approved oncology therapeutic product labeling.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2026–23005 Filed 11–10–26; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF THE TREASURY

Internal Revenue Service

26 CFR Part 1

[REG–117199–25]

RIN 1545–BR97

Federal Scholarship Tax Credit; Hearing

AGENCY: Internal Revenue Service (IRS), Treasury.

ACTION: Notification of change to telephonic-only public hearing on a proposed rulemaking.

SUMMARY: This document announces that the public hearing scheduled for December 15, 2026, at 10 a.m. ET, for the notice of proposed rulemaking and notice of public hearing (REG–117199–25) published in the **Federal Register** on October 2, 2026, has been changed to a telephonic-only hearing. These proposed regulations would provide guidance regarding the non-refundable Federal tax credit for qualified contributions to scholarship granting organizations to fund qualified elementary and secondary school education scholarships.

DATES: The public hearing scheduled to be held on December 15, 2026, at 10 a.m. ET, has been changed to a telephonic-only hearing.

ADDRESSES: Public comments that have been submitted on the proposed regulations (REG–117199–25) are available on the Federal eRulemaking Portal at *https://www.regulations.gov.*

FOR FURTHER INFORMATION CONTACT: Concerning the proposed regulations, Constance Chien, (202) 317–7002, or Andrew Fahmy, (202) 317–3840; concerning submissions of comments and the public hearing, the Publications and Regulations Section at (202) 317–6901 (not toll-free numbers) or by email at *publichearings@irs.gov* (preferred).

SUPPLEMENTARY INFORMATION: The subject of the public hearing is the notice of proposed rulemaking and notice of public hearing (REG–117199–25) published in the **Federal Register** on October 2, 2026 (91 FR 62818). This hearing will now be held in a telephonic-only format.

The rules of 26 CFR 601.601(a)(3) apply to the public hearing. Individuals who wish to present oral comments at the public hearing are required to submit an outline of the topics to be discussed as well as the time to be devoted to each topic by December 1, 2026. Individuals who made requests to testify either in-person or by telephone prior to this Notification of change, and individuals who subsequently make timely requests to testify by telephone will receive the telephone number and access codes for the public hearing. A period of 10 minutes will be allotted to each person testifying.

Individuals who have already sent an email to *publichearings@irs.gov* to request to attend the hearing by telephone or in person do not need to make a second request to attend the hearing now being held by telephone only. The IRS will provide those individuals with a telephone number and access code for the rescheduled hearing by email.

An agenda showing the scheduling of the speakers will be prepared after the deadline for receiving outlines has passed. Copies of the agenda will be available via the Federal eRulemaking Portal (*https://www.regulations.gov*) under the title of Supporting & Related Material.

Individuals who want to attend the public hearing by telephone without testifying must also send an email to *publichearings@irs.gov* to receive the telephone number and access code for the hearing. The subject line of the email must contain the regulation number (REG–117199–25) and the language ''ATTEND Hearing Telephonically.'' For example, the subject line may say: Request to ATTEND Hearing Telephonically for REG–117199–25. Requests to attend the hearing must be received by 5 p.m. ET on Thursday, December 10, 2026.

Public hearings will be made accessible to people with disabilities. To request special assistance during a public hearing, please contact the Publications and Regulations Section of the Office of Associate Chief Counsel (Procedure and Administration) by sending an email to *publichearings@irs.gov* (preferred) or by telephone at (202) 317–6901 (not a toll-free number) no later than Wednesday, December 9, 2026.

Any additional questions regarding speaking at or attending the hearing may

also be emailed to *publichearings@irs.gov*.

Regina L. Johnson,

Federal Register Liaison, Publications and Regulations Section, Associate Chief Counsel, (Procedure and Administration).

[FR Doc. 2026–23032 Filed 11–10–26; 8:45 am]

BILLING CODE 4831–GV–P

POSTAL SERVICE

39 CFR Part 501

Authorization To Manufacture and Distribute Postage Evidencing Systems

AGENCY: Postal Service.

ACTION: Proposed rule.

SUMMARY: The Postal Service is amending its Postage Evidencing Systems regulations to align with existing practices and operational realities to better address circumstances where advances by a resetting company on any given day exceed the daily average funds advanced amount maintained on deposit with the Postal Service. The regulations currently allow resetting companies to advance postage to customers by a process where the resetting company maintains a daily average advance balance with the Postal Service. The current regulation contemplates that the amount on deposit will always cover amounts advanced and does not permit a resetting company to advance funds to customers in excess of the amount maintained on deposit. Operational realities will create circumstances where it is necessary to advance funds in excess of the amount on deposit and the average daily balance rule represents a practical and fair method to address circumstances where excess advances occur.

DATES: Comments must be received on or before December 14, 2026.

ADDRESSES: Mail or deliver comments to the Treasurer, United States Postal Service, 475 L'Enfant Plaza SW, RM 8307, Washington, DC 20260. Email comments, containing the name and address of the commenter, to: *PCFederalRegister@usps.gov,* with a subject line of ''[Date], Authorization to Manufacture and Distribute Postage Evidencing Systems.'' Faxed comments are not accepted.

You may inspect and photocopy all written comments at USPS® Headquarters Library, 475 L'Enfant Plaza SW, 11th Floor N, Washington, DC by appointment only between the hours of 9 a.m. and 4 p.m., Monday through Friday by calling 1–202–268–2906 in advance.

FOR FURTHER INFORMATION CONTACT: Michael Milligan, Treasurer, United States Postal Service, 475 L'Enfant Plaza SW, RM 8307, Washington, DC 20260, phone number (202) 384–7296.

SUPPLEMENTARY INFORMATION: The Postal Service invites public comment on the following proposed amendments to the Code of Federal Regulations.

All submitted comments and attachments are part of the public record and subject to disclosure. Do not enclose any material in your comments that you consider to be confidential or inappropriate for public disclosure.

List of Subjects in 39 CFR Part 501

Administrative practice and procedure, Postal Service.

PART 501—AUTHORIZATION TO MANUFACTURE AND DISTRIBUTE POSTAGE EVIDENCING SYSTEMS

■ 1. The authority citation for part 501 continues to read as follows:

Authority: 5 U.S.C. 552(a); 39 U.S.C. 101, 401, 403, 404, 410, 2601, 2605; Inspector General Act of 1978, as amended (Pub. L. 95–452, as amended); 5 U.S.C. App. 3.

■ 2. Amend § 501.15 by revising paragraph (c) to read as follows:

§ 501.15 Computerized Meter Resetting System.

* * * * *

(c) If the RC chooses to offer advancement of funds to customers, the RC is required to maintain a deposit with the Postal Service equal to at least one (1) day's average funds advanced. The provider shall transfer to the Postal Service funds equal to the net amount advanced for any given day on or before the morning of the next business day. The Postal Service shall not be liable for any payment made by the RC on behalf of a customer that is not reimbursed by the customer, since the RC is solely responsible for the collection of advances made by the RC.

* * * * *

Jeffrey Boblick,

Attorney, Ethics & Legal Compliance.

[FR Doc. 2026–23064 Filed 11–10–26; 8:45 am]

BILLING CODE 7710–12–P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 52

[EPA–R05–OAR–2026–4753; FRL–9802.1–01–R5]

Approval and Promulgation of Air Quality Implementation Plans; Michigan; Withdrawal of the Federal Implementation Plan for the Detroit Sulfur Dioxide Area

AGENCY: Environmental Protection Agency (EPA).

ACTION: Proposed rule.

SUMMARY: The U.S. Environmental Protection Agency (EPA) is proposing to withdraw the Federal Implementation Plan (FIP), promulgated on October 12, 2022 (the ''2022 FIP''), for attaining the 2010 1-hour primary sulfur dioxide (SO_2) National Ambient Air Quality Standard (NAAQS) in the Detroit area. On May 19, 2025, the EPA approved a revision to Michigan's State Implementation Plan (SIP) for attaining the 2010 1-hour primary SO_2 NAAQS in the Detroit area, rendering the 2022 FIP duplicative. The EPA is proposing this action pursuant to Clean Air Act (CAA) section 110.

DATES: Comments must be received on or before December 28, 2026.

Virtual Public Hearing. If anyone contacts the EPA requesting to present at a virtual public hearing on or before November 27, 2026, the Agency will hold a virtual public hearing on December 14, 2026.

To request to present at a virtual public hearing, or to pre-register to attend the hearing, if one is held, please use the online registration form available at *https://www.epa.gov/mi/detroit-so2-federal-implementation-plan* or contact Abigail Teener at (312) 353–7314 or by email at *teener.abigail@epa.gov.* The EPA is asking all hearing attendees to register, even those who do not intend to present. The last day to request to present at the hearing will be November 27, 2026. If no request to present at the virtual public hearing is received by 11:59 p.m. Central Time (CT) on November 27, 2026, the EPA will not hold the hearing. If a virtual hearing is held, the EPA will accept registration until the start of the hearing.

The EPA will announce the status of the hearing on November 30, 2026 on the public hearing website at *https://www.epa.gov/mi/detroit-so2-federal-implementation-plan.* Alternatively, interested parties may contact Abigail Teener at (312) 353–7314 or by email at *teener.abigail@epa.gov* to find out if the hearing is being held.